|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<b>Methods:</b> We reviewed the published pharmacokinetic (PK) and pharmacodynamic (PD) clinical data that report potential -or absence of- drug interactions between second-generation agents (SGAs) and CVD drugs most commonly used in cardiology, including antiplatelet drugs and anticoagulants, statins, beta-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics and the antiarrhythmic drugs amiodarone and digoxin.
|
30707042 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
171 Indigenous people aged ≥20 years of age who had at least one clinical diagnosis of a CVD event, or in Canada and Australia had a 5-year CVD risk ≥15%, and were prescribed at least two of the following CVD medication classes: statin, aspirin, ACE inhibitors and beta blockers.
|
29371275 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites.
|
10669647 |
2000 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) gene I/D polymorphism has been associated with cardiovascular diseases and with progression of IgAN.
|
11014979 |
2000 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ACE polymorphisms have recently been shown to associate with worse renal and or cardiovascular outcome, with the D allele widely reported as a risk factor for cardiovascular disease.
|
11142763 |
2000 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) abnormalities have been implicated in the pathogenesis of various cardiovascular diseases.
|
11401071 |
2001 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
LHGDN |
Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.
|
11985486 |
2002 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.
|
11985486 |
2002 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) gene insertion(I)/deletion(D) polymorphism influences the outcome of a number of cardiovascular diseases.
|
15806540 |
2005 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACEIs) have been used in the treatment of various cardiovascular diseases.
|
16144506 |
2005 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin I-converting enzyme inhibitors (ACEi), which are used to treat common cardiovascular diseases, are associated with a potentially life-threatening adverse reaction known as angioedema (AE-ACEi).
|
16175507 |
2005 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin I-converting enzyme (ACE) insertion/deletion (I/D) polymorphism has been associated with the genetic susceptibility to several cardiovascular diseases; however, its association with cardiovascular risk factors (CRFs) in different populations needs to be clarified.
|
19371224 |
2009 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) gene polymorphism was previously studied in some cardiovascular diseases.
|
19847428 |
2011 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) is a vital enzyme in the renin-angiotensin-aldosterone system, and there are reports in the literature describing its role in the development of cardiovascular system diseases, with I/D polymorphism of the ACE gene.
|
20449805 |
2010 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) is a vital enzyme in the renin-angiotensin-aldosterone system; it is involved in the development of cardiovascular system diseases linked to I/D polymorphism of the ACE gene.
|
21038299 |
2010 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin II receptor blockers) are already widely used for the treatment and prevention of cardiovascular disease and their potential role in other disease states has become increasingly recognized.
|
22757959 |
2012 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) has been implicated in multiple biological system, particularly cardiovascular diseases.
|
23469169 |
2013 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) and ACE2 are key regulators of the renin-angiotensin system, which has been shown to participate in a series of cardiovascular diseases.
|
25237166 |
2015 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) gene I/D polymorphism is associated with many cardiovascular diseases.
|
26125265 |
2015 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
ACE I/D polymorphism has been reported to be associated with various cardiovascular diseases.
|
26985916 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin-Converting Enzyme Insertion/Deletion polymorphism (ACE I/D polymorphism) has also be linked to cardiovascular diseases.
|
27022914 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin I converting enzyme (ACE) insertion/deletion (I/D) polymorphism is thought to affect renin-angiotensin system (RAS) activity and development of cardiovascular disease; significant associations between I/D polymorphism and atherosclerosis, stroke, nephropathy, and early mortality were already found.
|
28190172 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors (ACEI) are widely used in the management of cardiovascular diseases but with significant interindividual variability in the patient's response.
|
28587581 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACE-I) display vasoprotective activity and represent the cornerstone in the treatment of cardiovascular diseases.
|
28700133 |
2018 |